Search
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawnChymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
Ivermectin
go.drugbank.com/drugs/DB00602ApprovedInvestigationalVet approved[L31453] Ivermectin is mainly used in humans in the treatment of onchocerciasis, but may also be effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis … [L31453] Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de
Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbsProducts: I-Dectin 0.5 % Pour-On, Vimectin 0.5% w/v Pour OnDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … use to cause vomiting in poisoning.
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approved[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578] … Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3.
Synonyms: O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosineMixtures: Np Thyroid 90, NP Thyroid 30Cycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.